Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second cohort of patients. (A) Abundance of miR-146a-5p and miR-24-3p in glomerular samples from additional patients with DN and FSGS on the basis of qPCR analysis. (B) Log2 fold differences of FSGS/DN from microRNA-sequencing analysis of original samples and qPCR analysis of new validation samples. *P<0.05; P=0.17 for miR-24-3p. Maria Angeles Baker et al. JASN 2017;28:2985-2992 ©2017 by American Society of Nephrology